Hey, wait a sec­ond. What about Roche’s PhI­II he­mo­phil­ia A drug?

Large­ly over­shad­owed by Bio­Marin’s po­ten­tial­ly land­mark gene ther­a­py re­sults for he­mo­phil­ia A, a group from Roche’s Chugai sub­sidiary turned up at the same sci­en­tif­ic con­fer­ence this week to spot­light up­dat­ed ev­i­dence that their bis­pe­cif­ic an­ti­body emi­cizum­ab dra­mat­i­cal­ly slashed the rate of bleed­ing episodes in a small but sig­nif­i­cant clin­i­cal tri­al.

Emi­cizum­ab, for­mer­ly ACE910, has been re­peat­ed­ly tapped by Roche’s Daniel O’Day as a top block­buster can­di­date for the phar­ma gi­ant. But now the in­jectable will have to com­pete for at­ten­tion with Bio­Marin and ri­vals who are work­ing with once-and-done gene ther­a­pies that promise to fix the bi­o­log­ic dys­func­tion that pre­vents nor­mal clot­ting in pa­tients’ blood.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.